Gilead, Public Patent Foundation infectious news

Gilead said the U.S. Patent and Trademark Office confirmed the patentability of U.S. Patent No. 6,043,230, with no reduction in the scope of claims. The patent covers Gilead's Viread tenofovir. The company said the decision is final and cannot be appealed. The ‘230 patent is the first of four Viread patents being reexamined by the PTO. The other three patents remain under review. ...